CSIMarket
 
Summit Therapeutics Inc   (SMMT)
Other Ticker:  
 
 
Price: $4.6200 $-0.13 -2.737%
Day's High: $5.02 Week Perf: 7.44 %
Day's Low: $ 4.57 30 Day Perf: 3.82 %
Volume (M): 9,768 52 Wk High: $ 5.22
Volume (M$): $ 45,127 52 Wk Avg: $2.36
Open: $4.80 52 Wk Low: $1.30



 Market Capitalization (Millions $) 2,870
 Shares Outstanding (Millions) 621
 Employees 70
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -615
 Cash Flow (TTM) (Millions $) -577
 Capital Exp. (TTM) (Millions $) 0

Summit Therapeutics Inc
Summit Therapeutics Inc is a biopharmaceutical company founded in 2003 and based in Cambridge, England, with additional offices in Oxford, UK, and Cambridge, Massachusetts, USA. It specializes in developing innovative therapies for rare and infectious diseases.

Summit's mission is to discover, develop and commercialize novel medicines that target some of the most challenging diseases in the world. The company has a particular focus on developing drugs with macrocyclic chemistry, which can be used to create highly specific and potent drugs that are efficient in treating specific diseases.

One of Summit's flagship products is Ridinilazole, an antibiotic drug that is being developed to treat Clostridioides difficile (CDI), a debilitating and challenging infection that affects millions of people worldwide. CDI is responsible for several deaths each year and is a major public health concern.

Ridinilazole has been shown to be more effective than the current standard of care, Vancomycin, and has fewer side effects. In clinical trials, the drug has demonstrated a higher cure rate and a lower rate of recurrence than Vancomycin.

Summit also has a partnership with Cyclica, a biotech company specializing in AI-driven drug discovery. The collaboration aims to develop macrocycle-derived drug candidates using Cyclica's Ligand Express platform to analyze and predict the binding affinity of large and complex molecules.

Summit's portfolio includes a pipeline of products in various stages of development, targeting conditions such as: Duchenne muscular dystrophy, Charcot-Marie-Tooth disease, Rett syndrome, and others. The company's research is supported by a team of experienced scientists and industry leaders, who have a proven track record of drug discovery and development.

In addition, the company works closely with international regulatory authorities, agencies and partners to advance its programs and ensure that they meet the highest standards of safety and efficacy.

Summit Therapeutics Inc is traded on the NASDAQ exchange under the symbol SMMT.


   Company Address: 601 Brickell Key Drive, Suite 1000 Miami 33131 FL
   Company Phone Number: 460-8308   Stock Exchange / Ticker: NASDAQ SMMT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases Presented at ELCC 2024

Published Thu, Mar 14 2024 11:00 AM UTC

Summit Therapeutics Inc. (NASDAQ: SMMT) recently announced the forthcoming presentation of data on their novel bispecific antibody, ivonescimab, at the 2024 European Lung Cancer Congress (ELCC 2024). The data showcases the intracranial anti-tumor activity and safety of ivonescimab in patients with non-small cell lung cancer (NSCLC) and brain metastases.Background:Managing br...

Summit Therapeutics Inc

2. Summit Therapeutics Inc. Shows Promise with Innovative Ivonescimab Drug in Financial Fourth Quarter of 2023

Miami, FL - Summit Therapeutics Inc. (NASDAQ: SMMT) recently reported its financial results for the fourth quarter and year-ended December 31, 2023. The innovative healthcare company, known for its groundbreaking clinical programs aimed at providing new treatment options for patients with infectious diseases, also provided updates on its operational progress. These updates were presented at the 42nd Annual J.P. Morgan Healthcare Conference, held in San Francisco, CA.
One of the key highlights of the updates is the progress of Ivonescimab (SMT112), an investigational bispecific antibody that combines the effects of immunotherapy with anti-angiogenesis. Ivonescimab has the potential to become a first-in-class drug, and Summit Therapeutics is optimistic about its future trajectory. The company believes that Ivonescimab, along with other potential corporate factors, could result in significant growth.

Product Service News

Summit Therapeutics Reveals Encouraging Ivonescimab Phase II Results and Anticipated Growth Catalysts at Prestigious J.P. Morgan Healthcare Conference

Published Mon, Jan 8 2024 2:00 PM UTC

Summit Therapeutics, a ground-breaking, revolutionary healthcare company renowned for its pioneering clinical programmes aimed to bring new treatment options for patients suffering from infectious diseases, recently proclaimed ground-breaking updates in the progress of its promising drug, Ivonescimab, at the 42nd Annual J.P. Morgan Healthcare Conference, held in San Francisc...

Summit Therapeutics Inc

Third Quarter of 2023 Showcases Resilient Revenue for Major Pharmaceutical Preparations Companies

Over the past five days, shares of Summit Therapeutics Inc (NASDAQ: SMMT) have experienced a decline of -2.05%. This drop adds to the company's year-to-date performance, which is currently at -61.8%. Furthermore, the shares are currently trading on the NASDAQ at -10.8% below their 52-week average.
For the fiscal period ending on September 30, 2023, Summit Therapeutics Inc reported a loss of $-0.03 per share. This is an improvement compared to the loss of $-0.14 per share from the previous year, but a slight increase from the loss of $-0.02 per share from the prior reporting season. The revenue for this period remained unchanged at $0.00 million, compared to $0.22 million in the same reporting season the previous year and sequentially from $0.00 million.

Business Update

Summit Therapeutics Inc. Reports Promising Progress and Strong Financial Results, Aims for Revolutionary Biopharmaceutical Breakthrough

Published Tue, Nov 7 2023 12:00 PM UTC


Summit Therapeutics Reports Strong Financial Results and Promising Operational Progress for Q3 and Nine Months Ended September 30, 2023
Summit Therapeutics Inc. (NASDAQ: SMMT) has announced its financial results and provided an update on its operational progress for the third quarter and nine months ended September 30, 2023. The company's innovative and potentially ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com